Citation Tools
PDFSection 2: Selection, Procurement and Distribution
2SPD-006 Assessment of regorafenib, ramucirumab and cabozantinib as secondline therapy in hepatocarcinoma and alfa-fetoprotein value ≥400 ng/mL
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 2SPD-006 Assessment of regorafenib, ramucirumab and cabozantinib as secondline therapy in hepatocarcinoma and alfa-fetoprotein value ≥400 ng/mL